Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCOT adaptive platform trial for hospitalized adults with COVID-19
ACTRN12620000445976Phase 3Recruiting
- Sponsor
- University of Melbourne
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Nafabelltan, enoxaparin, tinzaparin, dalteparin, nirmatrelvir + ritonavir and 1 more in coronavirus disease 2019 (COVID-19) (11 arms), sponsored by University of Melbourne. Started Jul 2020; status: recruiting.
02
Drugs
Nafabelltanenoxaparintinzaparindalteparinnirmatrelvir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000445976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000445976.